geneUp	minExonUp	maxExonUp	geneDown	minExonDown	maxExonDown	source	sourceEvent	sourceUrls	nctId	title	acronym	genderCriterium	countriesAndCities	hospitalsPerCity	treatment	treatmentApproachesDrugClass	treatmentApproachesTherapy	applicableCancerType	applicableDoid	blacklistCancerTypes	level	direction	evidenceUrls	date	description
EGFR	1	2	EGFR	8	9	CKB_EVIDENCE	fusion	http							Osimertinib			Lung Cancer	X		A	RESPONSIVE	http,http	2021-02-03	efficacy evidence A
EML4			ALK			CKB_EVIDENCE	fusion	http							Crizotinib			Lung Cancer	X		A	RESPONSIVE	http,http	2021-02-04	efficacy evidence B
PCM1			JAK2			CKB_TRIAL	fusion	http	NCT1	study1	study1	male	Germany(Koln;Frankfurt)	Koln(Cellitinnen-Krankenhaus St. Marien),Frankfurt(Burgerhospital Frankfurt)	Ruxolitinib			Leukemia	X		B	RESPONSIVE	http,http		
